Insider BuyTMCI· · June 1, 2026, 8:39 PM UTC
Treace Medical founder-CEO buys $178K of TMCI
John Treace adds shares of the bunion-surgery specialist.
John Treace, founder and CEO of Treace Medical Concepts, disclosed a $178K open-market purchase of TMCI at a 55 score. A founder-CEO buying after a drawdown is a conviction read worth surfacing.
Reporting insider: Treace John T. · Chief Executive Officer · discretionary, open-market
The filing, structured
| Security | Date | Type | Shares | Price | Owned after | Holding |
|---|---|---|---|---|---|---|
| Common Stock | 2026-06-01 | Open-market purchase | +50K | $3.56 | 7.32M | Direct |
FAQ
- What insider transaction did TREACE MEDICAL CONCEPTS, INC. (TMCI) report?
- John Treace, founder and CEO of Treace Medical Concepts, disclosed a $178K open-market purchase of TMCI at a 55 score. A founder-CEO buying after a drawdown is a conviction read worth surfacing.
- Who made the purchase at $TMCI?
- Treace John T., Chief Executive Officer, is the reporting insider on this Form 4, a purchase of about $178K.
- Was the $TMCI trade an open-market transaction or a 10b5-1 plan?
- The trade was a discretionary, open-market transaction — not executed under a pre-arranged 10b5-1 plan.
- What is the DEHY Score for this $TMCI filing?
- This filing scored 55 out of 100 on the DEHY Score, a 0–100 triage signal for how much analyst attention a filing warrants — not a price prediction.
Structured from public SEC data within seconds of filing. The DEHY Score is a 0–100 triage signal, not investment advice or a price prediction. See methodology.